Literature DB >> 20962870

Validation of recombinant Sendai virus in a non-natural host model.

U Griesenbach1, G McLachlan, T Owaki, L Somerton, T Shu, A Baker, P Tennant, C Gordon, C Vrettou, E Baker, D D S Collie, M Hasegawa, E W F W Alton.   

Abstract

We have previously shown that recombinant Sendai virus (SeV) vector, derived from murine parainfluenza virus, is one of the most efficient vectors for airway gene transfer. We have also shown that SeV-mediated transfection on second administration, although reduced by 60% when compared with levels achieved after a single dose, is still high because of the efficient transfection achieved by SeV vector in murine airways. Here, we show that these levels further decrease on subsequent doses. In addition, we validated SeV vector repeat administration in a non-natural host model, the sheep. As part of these studies we first assessed viral stability in a Pari LC Plus nebuliser, a polyethylene catheter (PEC) and the Trudell AeroProbe. We also compared the distribution of gene expression after PEC and Trudell AeroProbe administration and quantified virus shedding after sheep transduction. In addition, we show that bronchial brushings and biopsies, collected in anaesthetized sheep, can be used to assess SeV-mediated gene expression over time. Similar to mice, gene expression in sheep was transient and had returned to baseline values by day 14. In conclusion, the SeV vector should be strongly considered for lung-related applications requiring a single administration of the vector even though it might not be suitable for diseases requiring repeat administration.

Entities:  

Mesh:

Year:  2010        PMID: 20962870     DOI: 10.1038/gt.2010.131

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

Review 1.  Cystic Fibrosis Gene Therapy in the UK and Elsewhere.

Authors:  Uta Griesenbach; Kamila M Pytel; Eric W F W Alton
Journal:  Hum Gene Ther       Date:  2015-05       Impact factor: 5.695

2.  Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Authors:  Eric W F W Alton; Jeffery M Beekman; A Christopher Boyd; June Brand; Marianne S Carlon; Mary M Connolly; Mario Chan; Sinead Conlon; Heather E Davidson; Jane C Davies; Lee A Davies; Johanna F Dekkers; Ann Doherty; Sabrina Gea-Sorli; Deborah R Gill; Uta Griesenbach; Mamoru Hasegawa; Tracy E Higgins; Takashi Hironaka; Laura Hyndman; Gerry McLachlan; Makoto Inoue; Stephen C Hyde; J Alastair Innes; Toby M Maher; Caroline Moran; Cuixiang Meng; Michael C Paul-Smith; Ian A Pringle; Kamila M Pytel; Andrea Rodriguez-Martinez; Alexander C Schmidt; Barbara J Stevenson; Stephanie G Sumner-Jones; Richard Toshner; Shu Tsugumine; Marguerite W Wasowicz; Jie Zhu
Journal:  Thorax       Date:  2016-11-16       Impact factor: 9.139

Review 3.  Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties.

Authors:  Angélique Mottais; Tony Le Gall; Yann Sibiril; Julian Ravel; Véronique Laurent; Frédérique d'Arbonneau; Tristan Montier
Journal:  Biosci Rep       Date:  2017-11-17       Impact factor: 3.840

4.  Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors.

Authors:  Huibi Cao; Tiago N Machuca; Jonathan C Yeung; Jing Wu; Kai Du; Cathleen Duan; Kohei Hashimoto; Virginia Linacre; Allan L Coates; Kitty Leung; Jian Wang; Herman Yeger; Ernest Cutz; Mingyao Liu; Shaf Keshavjee; Jim Hu
Journal:  Mol Ther Nucleic Acids       Date:  2013-10-08       Impact factor: 10.183

5.  Intratracheal aerosolization of viral vectors to newborn pig airways.

Authors:  Ashley L Cooney; Patrick L Sinn
Journal:  Biotechniques       Date:  2020-03-06       Impact factor: 1.993

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.